Search Within

Kenneth Ho-Ming Yu

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (3)
Groups
  1. Advanced Practice Providers (10)
  2. Center for Pancreatic Cancer Research (10)
  3. Department of Medicine (10)
  4. Gastrointestinal Oncology Service (10)
  5. Nursing (10)
  6. Solid Tumor Oncology Division (10)

More Groups

People
  1. Eileen O'Reilly (10)
  2. Maeve Lowery (10)
  3. Ellen Hollywood (8)
  4. Marinela Capanu (8)
  5. David Kelsen (6)
  6. Kinh Gian Do (6)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (3)
  4. 2015 (1)
  5. 2014 (1)
  6. 2013 (1)
Publications
  1. Journal of Clinical Oncology (6)
  2. Annals of Oncology (1)
  3. Cancer (1)
  4. Clinical Cancer Research (1)
  5. European Journal of Cancer (1)
Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (1)
  3. Elsevier Inc. (1)
  4. Oxford University Press (1)
  5. Wiley Blackwell (1)

Results (10)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers
    Journal Article

    Lowery, M. A.; Bradley, M.; Chou, J. F.; Capanu, M.; Gerst, S.; Harding, J. J.; El Dika, I.; Berger, M.; Zehir, A.; Ptashkin, R.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis
    Meeting Abstract

    Yu, K. H.; Mantha, S.; Tjan, C.; Kaufmann, E. S.; Brenner, R.; Lowery, M. A.; Ku, G. Y.; Raj, N. P.; Shcherba, M.; Goldberg, Z.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis
    Meeting Abstract

    Yu, K.; Mantha, S.; Tjan, C.; Kaufmann, E.; Brenner, R. B.; Lowery, M.; Ku, G.; Raj, N.; Shcherba, M.; Goldberg, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
    Journal Article

    Lowery, M. A.; Kelsen, D. P.; Capanu, M.; Smith, S. C.; Lee, J. W.; Stadler, Z. K.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC)
    Meeting Abstract

    Lowery, M. A.; O'Reilly, E. M.; Harding, J. J.; Yu, K. H.; Cercek, A.; Hollywood, E.; Salehi, E.; Margona, E.; Bradley, M.; Witter, T.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Meeting Abstract

    Lowery, M. A.; Harding, J. J.; Yu, K. H.; Kelsen, D. P.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
    Journal Article

    Lowery, M. A.; Yu, K. H.; Kelsen, D. P.; Harding, J. J.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Cancer (2017)

    Fulltext@MSK | Save
  • Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC)
    Meeting Abstract

    Lowery, M. A.; Kelsen, D. P.; Smith, S. C.; Moore, M.; Kindler, H. L.; Golan, T.; Segal, A.; Hollywood, E.; Maynard, H.; Capanu, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Lowery, M. A.; Segal, M. F.; Smith, S. C.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; Salo-Mullen, E. E.; Hollywood, E.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Lowery, M. A.; Yu, K. H.; Capanu, M.; Stadler, Z. K.; Epstein, A. S.; Golan, T.; Segal, A.; Segal, M.; Salo-Mullen, E. E.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save